廣告
香港股市 將在 9 小時 24 分鐘 開市

  • 恒指

    17,284.54
    +83.27 (+0.48%)
     

  • 國指

    6,120.37
    +20.15 (+0.33%)
     

  • 上證綜指

    3,052.90
    +8.08 (+0.27%)
     

  • 道指

    37,919.75
    -541.17 (-1.41%)
     

  • 標普 500

    5,020.04
    -51.59 (-1.02%)
     

  • 納指

    15,490.14
    -222.61 (-1.42%)
     

  • Vix指數

    16.74
    +0.77 (+4.82%)
     

  • 富時100

    8,078.86
    +38.48 (+0.48%)
     

  • 紐約期油

    82.49
    -0.32 (-0.39%)
     

  • 金價

    2,342.00
    +3.60 (+0.15%)
     

  • 美元

    7.8281
    -0.0028 (-0.04%)
     

  • 人民幣

    0.9241
    -0.0006 (-0.06%)
     

  • 日圓

    0.0501
    -0.0001 (-0.24%)
     

  • 歐元

    8.3912
    +0.0155 (+0.18%)
     

  • Bitcoin

    64,093.62
    -765.88 (-1.18%)
     

  • CMC Crypto 200

    1,381.80
    -0.77 (-0.06%)
     

Why Gilead Sciences Stock Is Falling Today

Vandana Singh
·1 分鐘文章

Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology.

"Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, driven by Trodelvy and Cell Therapy," said Daniel O'Day, Gilead's Chairman & CEO.

Product sales decreased by 3% to $6.3 billion; excluding Veklury, product sales increased 15% to $5.7 billion.

HIV product sales increased 13% to $4.2 billion, with Biktarvy bringing in $2.7 billion. Cell Therapy product sales increased 64% to $448 million.

廣告

View more earnings on GILD

Veklury sales decreased by 63% to $573 million, primarily driven by lower rates of COVID-19-related hospitalizations in all regions.

The company reported adjusted EPS of $1.37, down 35% Y/Y, lagging the consensus of $1.54. The product gross margin was 86.2%, down from 87.4% a year ago.

Guidance: Gilead reaffirms FY23 sales guidance of $26-$26.5 billion versus the consensus of $26.73 billion. It forecasts adjusted EPS of $6.60-$7.00 compared to consensus of $6.84.

Price Action: GILD shares are down 2.25% at $81.67 on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Why Gilead Sciences Stock Is Falling Today originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.